Skip to main content

Table 1 Clinical and epidemiological characteristics of all HIV/HCV-coinfected patients stratified by FTO genotype

From: FTOrs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients

Characteristics All patients (number = 261) TT (number = 101) AT (number = 123) AA (number = 37) P-value
Gender (male) 74.7% (195) 73.3% (74) 74% (91) 81.1% (30) 0.625
Age (years) 40.9 (6.9) 40.6 (6.17) 41.1 (7.69) 42.1 (6.6) 0.849
HIV acquired by IVDU 85.4% (223) 85.1% (86) 83.7% (103) 91.9% (34) 0.556
Years since HCV infection 21 (8.4) 21.3 (8.35) 20.9 (8.25) 21.6 (7.8) 0.670
Prior AIDS 29.1% (76) 69.3% (70) 74.8% (92) 37.8% (14) 0.302
cART 84.7% (221) 82.2% (83) 87.8% (108) 81.1% (30) 0.410
Time on cART (years) 4.8 (5) 4.6 (4.9) 5 (4.8) 4.7 (5.1) 0.350
Current cART protocols      
Any NRTIs + any PI 24.5% (64) 25.7% (26) 25.2% (31) 18.9% (7) 0.691
Any NRTIs + PI + NNRTI 1.1% (3) 1% (1) 1.6% (2) 0% (0) 0.705
Any NRTIs + any NNRTI 51.3% (134) 50.5% (51) 51.2% (63) 54.1% (20) 0.933
Only NRTIs 7.3% (19) 5% (5) 9.8% (12) 5.4% (2) 0.346
Specific antiretroviral drugs      
Zidovudine 27.2% (71) 25.7% (26) 30.1% (37) 21.6% (8) 0.547
Stavudine 26.1% (68) 24.8% (25) 28.5% (35) 21.6% (8) 0.659
Didanosine 16.9% (44) 18.8% (19) 13.8% (17) 21.6% (8) 0.431
Tenofovir 26.8% (70) 28.7% (29) 22% (27) 37.8% (14) 0.138
Abacavir 16.1% (42) 9.9% (10) 21.1% (26) 16.2% (6) 0.075
Efavirenz 30.3% (79) 29.7% (30) 30.1% (37) 32.4% (12) 0.951
Ritonavir (r) 6.1% (16) 5.9% (6) 7.3% (9) 2.7% (1) 0.588
Lopinavir/r 12.3% (32) 10.9% (11) 12.2% (15) 16.2% (6) 0.700
Saquinavir 1.1% (3) 0% (0) 1.6% (2) 2.7% (1) 0.332
Fosamprenavir 2.3% (6) 3% (3) 2.4% (3) 0% (0) 0.582
HIV markers      
Nadir CD4+ T-cells (cells/μL) 204 (223) 210 (262) 195 (221) 210 (201) 0.157
Nadir CD4+ <200 cells/μL 49% (128) 46.5% (47) 52% (64) 45.9% (17) 0.658
CD4+ T cells/μL 465 (325) 460 (435) 472 (234) 456 (251) 0.313
CD4+ ≥500 cells/μL 43.5% (113) 55.4% (56) 57.4% (70) 43.2% (16) 0.959
HIV-RNA <50 copies/mL 76.9% (200) 75% (75) 78% (96) 78.4% (29) 0.844
HCV markers      
HCV-genotype 1/4 73.4% (185) 68.8% (66) 75% (90) 80.6% (29) 0.339
HCV-RNA ≥500,000 UI/ml 75.1% (187) 29.6% (29) 23.5% (27) 83.3% (30) 0.275
IFNL3 rs12980275 (AA) 47.5% (122) 47.5% (48) 50% (61) 38.2% (13) 0.557
  1. Categorical variables are expressed in percentage (absolute count).; continuous variables are expressed in median (interquartile range) P-values were estimated with Chi-square test for categorical variable and linear regression test for continuous variable. AIDS, acquired immunodeficiency syndrome; cART, combination antiretroviral therapy; HCV, hepatitis C virus; HCV-RNA, HCV plasma viral load; HIV, human immunodeficiency virus; HIV-RNA, HIV plasma viral load; IVDU, intravenous drug users; NNRTI, no nucleoside analog reverse-transcriptase inhibitors; NRTI, nucleoside analog reverse-transcriptase inhibitors; PI, protease inhibitors.